Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?

Recent advances in the efficacy and tolerability of hepatitis C treatments and the introduction of a universal access scheme for the new Direct Acting Antiviral (DAA) therapies in March 2016, has resulted in a rapid increase in the uptake of hepatitis C treatment in Australia. Despite these positive...

Descripción completa

Detalles Bibliográficos
Autores principales: Madden, Annie, Hopwood, Max, Neale, Joanne, Treloar, Carla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267952/
https://www.ncbi.nlm.nih.gov/pubmed/30500863
http://dx.doi.org/10.1371/journal.pone.0207226

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267952/
https://www.ncbi.nlm.nih.gov/pubmed/30500863
http://dx.doi.org/10.1371/journal.pone.0207226

Ejemplares similares